Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range

Biochimie

Volumn 89, Issue 10, 2007, Pages 1228-1233

  Meryet Figuieres M ^a   Resina, S ^a   Lavigne, C ^b   Barlovatz Meimon, G ^c   Lebleu, B ^a   Thierry, A R ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b UNIVERSITÉ DE MONCTON   (Canada)

^c UNIVERSITY OF EVRY   (France)

Author keywords

Breast cancer; Delivery; Plasminogen activator inhibitor type I; siRNA

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; LIPOSOMAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MICROCHEMISTRY; NANOTECHNOLOGY; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34848876930     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.03.017     Document Type: Article

References (26)

1. Chazaud B., Ricoux R., Christov C., Plonquet A., Gherardi R.K., and Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 160 (2002) 237-246
2. Bajou K., Lewalle J.M., Martinez C.R., Soria C., Lu H., Noel A., and Foidart J.M. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int. J. Cancer 100 (2002) 501-506
3. Mazar A.P., Henkin J., and Goldfarb R.H. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3 (1999) 15-32
4. Brooks T.D., Wang S.W., Brunner N., and Charlton P.A. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 15 (2004) 37-44
5. Hecke A., Brooks H., Meryet-Figuiere M., Minne S., Konstantinides S., Hasenfuss G., Lebleu B., and Schafer K. Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA. Thromb. Haemost. 95 (2006) 857-864
6. Felgner P.L., Barenholz Y., Behr J.P., Cheng S.H., Cullis P., Huang L., Jessee J.A., Seymour L., Szoka F., Thierry A.R., Wagner E., and Wu G. Nomenclature for synthetic gene delivery systems. Hum. Gene Ther. 8 (1997) 511-512
7. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
8. Gitlin L., Karelsky S., and Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418 (2002) 430-434
9. Leung R.K., and Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107 (2005) 222-239
10. Lingor P., Michel U., Scholl U., Bahr M., and Kugler S. Transfection of "naked" siRNA results in endosomal uptake and metabolic impairment in cultured neurons. Biochem. Biophys. Res. Commun. 315 (2004) 1126-1133
11. Thierry A.R., Lunardi-Iskandar Y., Bryant J.L., Rabinovich P., Gallo R.C., and Mahan L.C. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9742-9746
12. Thierry A.R., Rabinovich P., Peng B., Mahan L.C., Bryant J.L., and Gallo R.C. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 4 (1997) 226-237
13. Lavigne C., and Thierry A.R. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem. Biophys. Res. Commun. 237 (1997) 566-571
14. Thierry A.R., Abes S., Resina S., Travo A., Richard J.P., Prevot P., and Lebleu B. Comparison of basic peptides- and lipid-based strategies for the delivery of splice correcting oligonucleotides. Biochim. Biophys. Acta. 1758 (2006) 364-374
15. Dondi E., Rogge L., Lutfalla G., Uze G., and Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. J. Immunol. 170 (2003) 749-756
16. Lutfalla G., and Uze G. Performing quantitative reverse-transcribed polymerase chain reaction experiments. Methods Enzymol. 410 (2006) 386-400
17. Aksentijevich I., Pastan I., Lunardi-Iskandar Y., Gallo R.C., Gottesman M.M., and Thierry A.R. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum. Gene Ther. 7 (1996) 1111-1122
18. Baudard M., Flotte T.R., Aran J.M., Thierry A.R., Pastan I., Pang M.G., Kearns W.G., and Gottesman M.M. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. Hum. Gene Ther. 7 (1996) 1309-1322
19. Tavitian B., Marzabal S., Boutet V., Kuhnast B., Terrazzino S., Moynier M., Dolle F., Deverre J.R., and Thierry A.R. Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging. Pharm. Res. 19 (2002) 367-376
20. Lavigne C., Lunardi-Iskandar Y., Lebleu B., and Thierry A.R. Cationic liposomes/lipids for oligonucleotide delivery: application to the inhibition of tumorigenicity of Kaposi's sarcoma by vascular endothelial growth factor antisense oligodeoxynucleotides. Methods Enzymol. 387 (2004) 189-210
21. Schmutz M., Durand D., Debin A., Palvadeau Y., Etienne A., and Thierry A.R. DNA packing in stable lipid complexes designed for gene transfer imitates DNA compaction in bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 12293-12298
22. Hamada M., Ohtsuka T., Kawaida R., Koizumi M., Morita K., Furukawa H., Imanishi T., Miyagishi M., and Taira K. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. 12 (2002) 301-309
23. Kappler M., Bache M., Bartel F., Kotzsch M., Panian M., Wurl P., Blumke K., Schmidt H., Meye A., and Taubert H. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 11 (2004) 186-193
24. Ning S., Fuessel S., Kotzsch M., Kraemer K., Kappler M., Schmidt U., Taubert H., Wirth M.P., and Meye A. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int. J. Oncol. 25 (2004) 1065-1071
25. Judge A.D., Bola G., Lee A.C., and MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13 (2006) 494-505
26. S. Resina, R. Kole, A. Travo, B. Lebleu, A.R. Thierry, Switching on transgene expression by correcting aberrant splicing with using multi-targeting steric block oligonucleotides, J. Gen. Med., in press.